ClinicalTrials.gg
RecruitingNCT07601074Updated Nov 6, 2026

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

A Phase 2 interventional study of Lopinavir / ritonavir in Human Papilloma Virus (HPV) and High-risk Human Papillomavirus Infection, sponsored by Daré Bioscience, Inc.. Recruiting at 11 sites in United States. Open to female participants aged 22 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Daré Bioscience, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 6, 2026Site recruiting status changed7 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
22 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Papilloma with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Papilloma · United States.

Planned enrollment
23rd of 39
118 · median 155
Started
2026
with 3 others
Phase 2
7 of 51
3 open now
Primary completion
2027-10
later than 9 of 12 live
Registered
49th of 51
by date

Among the 51 studies in Papilloma with a site in United States, this one is the 23rd largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 9 of the 12 other live ones, and was the 49th registered.

Papilloma

89 studies on the registry are indexed under Papilloma; 20 are open to participants now.

Browse Papilloma studies →

Open to participants now

9 of the 51 studies in Papilloma with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Papilloma studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 22 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Papilloma with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days.

The study will look at two different doses of DARE-HPV and two different treatment durations of 14 and 21 days compared to a placebo group or 14 or 21 days of treatment.

03

Conditions studied

  • Human Papilloma Virus (HPV)
  • High-risk Human Papillomavirus Infection

Keywords

  • HPV
  • hrHPV
04

Who can participate

Ages eligible
22 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written prior to any study-specific procedures.
  2. Premenopausal women aged 22-50 years inclusive at the time of screening visit.
  3. Positive result for genital hrHPV (types 16, 18, or 'other') on at least 2 tests over the span of at least 12 months (history of persistent hrHPV infection for at least 12 months), based on review of participant's medical records. The visit 1 screening genital hrHPV test may be the second positive test.
  4. Generally, in good health with no disease as determined by the Investigator.
  5. Regular menstrual cycle with an approximate 28-day cycle OR women who are amenorrheic due to effective (such as levonorgestrel intrauterine system, or continuous oral contraception).
  6. Agree to refrain from vaginal douching, insertion of intravaginal devices (e.g., tampons, menstrual cups), and use of condoms for at least 48 hours before the first dose of study drug through at least 72 hours after the last dose of study drug.
  7. Agree to abstain from all vaginal and oral intercourse for at least 48 hours before the first dose of study drug through at least 72 hours after the last dose of study drug.
  8. Women at risk of pregnancy must use a highly effective form of birth control (confirmed by the Investigator) for the entire duration of the study. Rhythm methods and consistent use of condoms will not be considered as highly effective methods of birth control. Highly effective forms of birth control include:

    • Heterosexual abstinence
    • Vasectomized male partner (provided that the male partner is the sole sexual partner of the female participant with and that the vasectomized partner has received medical assessment of the surgical success);
    • Oral or transdermal combined ethinyl estradiol/progestin hormonal contraception associated with inhibition of ovulation;
    • Oral, injectable or implantable progestogen-only hormone contraception associated with inhibition of ovulation (e.g., Depo-Provera™, Nexplanon, Slynd);
    • Any effective copper intrauterine device/levonorgestrel intrauterine system;
    • Female sterilization by tubal occlusion or bilateral salpingectomy;
    • Supracervical hysterectomy.
  9. Ability and willingness to attend the necessary visits to the study center.
  10. Ability to comprehend all study related documentation, including written informed consent form, and complete all study-related tasks including daily diary.
  11. Be willing and able to adhere to the prohibitions and restrictions specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Any significant disease or disorder (e.g., cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the results of the study, or the participant's ability to participate in the study.
  2. Any abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening and at baseline, which in the opinion of the Investigator, may put the participant at risk because of her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
  3. Cytological abnormality of the uterine cervix defined as LSIL or mild cervical intraepithelial neoplasia (CIN1), or HSIL or moderate (CIN 2) or severe (CIN 3) histology, as proven by cytology or colposcopic collected within the 12 months prior to screening or cytology at screening.
  4. Pregnant, breastfeeding, or lactating women ( must have a negative urine pregnancy test at screening and at the start of treatment [i.e., Day 1]).
  5. Active pelvic infection (positive for gonorrhea or chlamydial infection, positive test and symptoms for bacterial vaginosis, candida vaginitis or trichomonal vaginitis). Participants with positive results can be treated and re-tested once during screening.
  6. Positive result for , antibody or .
  7. Currently taking systemic , biologics, intra-vaginal preparations, or any prescription that in the opinion of the Investigator could be a potential safety issue or interfere with the interpretation of the results.
  8. Previous exposure to lopinavir/ritonavir (within 3 months prior to screening), to the use of lopinavir/ritonavir or known allergy, , or intolerance to any component of lopinavir/ritonavir .
  9. Recent history (within 3 months prior to screening) of Stevens-Johnson syndrome, erythema multiforme, urticaria, or angioedema.
  10. Receipt of any product within 30 days or 5 half-lives prior to dosing.
  11. Participants who, in the opinion of the Investigator, do not understand the information and procedures of the study, or would not be compliant with them (in particular, the study restrictions and risks involved).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
118 participants (estimated)

Study arms

  • Active comparator
    DARE-HPV-LD 14 day

    14 day administration of DARE-HPV low dose

    Drug: Lopinavir / ritonavir

  • Active comparator
    DARE-HPV-LD 21 day

    21 day administration of DARE-HPV low dose

    Drug: Lopinavir / ritonavir

  • Active comparator
    DARE-HPV-HD 14 day

    14 day administration of DARE-HPV high dose

    Drug: Lopinavir / ritonavir

  • Active comparator
    DARE-HPV-HD 21 day

    21 day administration of DARE-HPV high dose

    Drug: Lopinavir / ritonavir

  • No intervention
    Placebo 14 day

    14 day administration of placebo product

  • No intervention
    Placebo 21 day

    21 day administration of placebo product

Interventions

  • DrugLopinavir / ritonavir

    A fixed-dose ration combination (12:1) of lopinavir and ritonavir in a vaginal capsule.

06

What researchers measure

Primary outcomes

  1. Efficacy Endpoint

    Proportion of participants with a negative high-risk human papillomavirus (hrHPV) qualitative test at 3 months post end of treatment

    Time frame: 90 days

Secondary outcomes

  1. Efficacy Endpoint

    Proportion of participants with a negative high-risk human papillomavirus (hrHPV) qualitative test at 2 months post end of treatment

    Time frame: 60 days

07

Study locations

11 of 11 sites recruiting
  • Velocity Clinical Research - Mobile
    Mobile, Alabama 36608, United States
    Recruiting
  • Precision Clinical Trials-Arizona
    Phoenix, Arizona 85032, United States
    Recruiting
  • Del Sol Research Management LLC
    Tucson, Arizona 85715, United States
    Recruiting
    • Wendy Hotz, President · Contactwhotz@delsolresearch.com · 520-526-0055
    • Paige Brainard, MD · Principal investigator
  • Applied Research Center of Arkansas/Cornerstone Clinic for Women
    Little Rock, Arkansas 72205, United States
    Recruiting
  • Planned Parenthood North Central States
    Saint Paul, Minnesota 55408, United States
    Recruiting
    • Christy Boraas, MD · Contactcboraas@ppncs.org · 651-696-5514
    • Christy Boraas, MD · Principal investigator
  • Velocity Clinical Research - Grand Island
    Grand Island, Nebraska 68803, United States
    Recruiting
  • AMR Clinical Columbus
    Columbus, Ohio 43213, United States
    Recruiting
  • Innovative Medical Research of Texas
    Houston, Texas 77065, United States
    Recruiting
  • Activian Clinical Research
    Pearland, Texas 77584, United States
    Recruiting
    • Lori Hoskins, Clinical Trials Associate Director · Contactlhoskins@activian.com · 713-795-5964
    • Yvette Poindexter, MD · Principal investigator
  • Alpine Research Organization, Inc.
    Layton, Utah 84041, United States
    Recruiting
  • Seattle Clinical Research Center
    Seattle, Washington 98104, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Oct 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 22, 2026
StartActual
Jul 17, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added. AMR Clinical Columbus is now Recruiting
Show 7 added (7 United States)
  • Del Sol Research Management LLC · Tucson, United States
  • Planned Parenthood North Central States · Saint Paul, United States
  • AMR Clinical Columbus · Columbus, United States
  • Activian Clinical Research · Pearland, United States
  • Velocity Clinical Research - Grand Island · Grand Island, United States
  • Innovative Medical Research of Texas · Houston, United States
  • Velocity Clinical Research - Mobile · Mobile, United States
across 3 updates, Oct 20, 2026 – Nov 6, 2026
Show all 3 updates
  1. Nov 6, 2026
    1 site added. AMR Clinical Columbus is now Recruiting
    Show site
    • Velocity Clinical Research - Mobile · Mobile, United States
  2. Oct 29, 2026
    2 sites added
    Show 2 added (2 United States)
    • Velocity Clinical Research - Grand Island · Grand Island, United States
    • Innovative Medical Research of Texas · Houston, United States
  3. Oct 20, 2026
    4 sites added
    Show 4 added (4 United States)
    • Del Sol Research Management LLC · Tucson, United States
    • Planned Parenthood North Central States · Saint Paul, United States
    • AMR Clinical Columbus · Columbus, United States
    • Activian Clinical Research · Pearland, United States
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07601074
Lead sponsor
Daré Bioscience, Inc.
Collaborators
Advanced Research Projects Agency for Health (ARPA-H)
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Jul 17, 2026
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Jessica Hatheway, MBA
Contact
jhatheway@darebioscience.com
(858)736-6026
Andrea Thurman, MD
study director · Daré Bioscience, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion